Antibiotic Resistance (ABR)

In the U.S., more than 2.8 million antimicrobial-resistant infections occur each year. More than 35,000 patients die annually as a result, according to CDC’s 2019 Antibiotic Resistance (AR) Threats Report. The Antibiotics Resistance (ABR) panel, developed by Blue Ridge Laboratories, is designed to expedite the diagnosis of an infection and help target treatment with non-resistant antimicrobials early in the course of disease. Antimicrobial resistance is one of the world’s most urgent public health problems.  Delays in diagnosis of an infection or prolongation of exposure to the wrong antibiotic increases this risk.  Our dedication to same day results prevents many of these adverse outcomes.